 TEL AVIV, Israel and NEW YORK, Feb. 02, 2022 GLOBE NEWSWIRE -- VBL Therapeutics Nasdaq: VBLT, a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will participate in a fireside chat at the Guggenheim Oncology Conference being held virtually on February 9 11, 2022. Management will also attend the BIO CEO Investor Conference being held as a hybrid event on February 14 17, 2022. 